Results 211 to 220 of about 42,703 (308)

Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease‐modifying antirheumatic drugs have influenced the use of leflunomide [PDF]

, 2015
Ashley M. Hopkins, Agnès Vitry, Catherine O‘Doherty, Susanna Proudman, Michael D. Wiese   +4 more
openalex   +1 more source

Correction to "Impact of Delay of Treatment With Disease-Modifying Antirheumatic Drugs in Psoriatic Arthritis: The CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry". [PDF]

ACR Open Rheumatol
europepmc   +1 more source

Personalized dose reduction strategies for biologic disease-modifying antirheumatic drugs for treating axial spondyloarthritis: a clinical and economic evaluation with predictive modeling. [PDF]

BMC Rheumatol
Binh BH, Phuong NTT, Hang VTT, Nhan NTT, Hoa NTN, Van Dung H.   +5 more
europepmc   +1 more source

Long-Standing Untreated or Inadequately Treated Seropositive Rheumatoid Arthritis in the Golden Age of Disease-Modifying Antirheumatic Drugs. [PDF]

Cureus
Arcilla CK, Kaeley GS, Thway M.
europepmc   +1 more source

Abatacept, Golimumab, and Sarilumab as Selected Bio-Originator Disease-Modifying Antirheumatic Drugs with Diverse Mechanisms of Action in Their Current Use in Treatment. [PDF]

J Clin Med
Kawczak P, Feszak IJ, Bączek T.
europepmc   +1 more source

Diverging effects of tumor necrosis factor inhibitors and conventional synthetic disease-modifying antirheumatic drugs on immunosenescence and inflammageing in rheumatoid arthritis: a cross-sectional analysis. [PDF]

Immun Ageing
Schwarz T, Almanzar G, Völkl S, Feuchtenberger M, Leierer J, Schmidt C, Deininger F, Tony HP, Schmalzing M, Prelog M.   +9 more
europepmc   +1 more source

Preferences for Tapering Biologic Disease-Modifying Antirheumatic Drugs Among People With Rheumatoid Arthritis: A Discrete Choice Experiment. [PDF]

Arthritis Care Res (Hoboken)
Chan SJ, Stamp LK, Treharne GJ, Cheung JMY, Dalbeth N, Grainger R, Stebbings S, Marra CA.   +7 more
europepmc   +1 more source

Efficacy and safety of conventional disease-modifying antirheumatic drugs in VEXAS syndrome: real-world data from the international AIDA network. [PDF]

Front Pharmacol
Vitale A, Leone F, Caggiano V, Hinojosa-Azaola A, Martín-Nares E, Guaracha-Basañez GA, Torres-Ruiz J, Ayumi Kawakami-Campos P, Hissaria P, Callisto A, Beecher M, Dagna L, Tomelleri A, Campochiaro C, Frassi M, Crisafulli F, Franceschini F, Hernández-Rodríguez J, Gómez-Caverzaschi V, Araújo O, Sfriso P, Bindoli S, Baggio C, Sbalchiero J, Sota J, Tufan A, Vasi I, Piga M, Cauli A, D'Agostino MA, De Paulis A, Mormile I, Mayrink Giardini HA, Cordeiro RA, Gavioli F, Lopalco G, Iannone F, Montecucco C, Monti S, Ruiz-Irastorza G, Soto-Peleteiro A, Triggianese P, Gurnari C, Viapiana O, Bixio R, Vitetta R, Conticini E, La Torre F, Ragab G, Batu ED, González-García A, Peña-Rodríguez M, Bocchia M, Wiesik-Szewczyk E, Jahnz-Rózyk K, de-la-Torre A, Balistreri A, Frediani B, Fabiani C, Cantarini L.   +59 more
europepmc   +1 more source

A Case of Oral Mucous Membrane Ulcers Caused by Disease-modifying Antirheumatic Drug (DMARD; Bucillamine)

, 2011
角田 愛美, 荒関 昭博, 高橋 悦子   +2 more
openalex   +2 more sources

Rituximab, Apremilast, and Upadacitinib as Selected Biosimilar and Targeted Synthetic Disease-Modifying Antirheumatic Drugs with Diverse Mechanisms of Action: Their Current Use in Slowing Down the Progression of Disease. [PDF]

J Clin Med
Kawczak P, Feszak IJ, Bączek T.
europepmc   +1 more source